What is sclerostin?
The problem: bone formation needs a braking system
Your skeleton must not build bone without limits. Excessive or poorly controlled bone formation could disrupt normal structure. To regulate this process, mature osteocytes release sclerostin, a protein that helps reduce osteoblast activity.
Sclerostin acts like a site supervisor telling the builders to slow down. It reduces signals that encourage osteoblasts to produce new bone.
This is useful in normal bone maintenance. However, in osteoporosis, the balance may already be tilted toward bone loss. A strong formation brake can then contribute to declining structural strength.
The solution: temporarily release the brake
Romosozumab binds to sclerostin and prevents it from exerting its usual inhibitory effect. This allows bone-forming signals to become more active.
The result is not simply “more calcium in the bones”. It is a coordinated change in bone remodelling, including:
- Increased activity from bone-forming osteoblasts.
- Increased bone mineral density (BMD).
- Improved trabecular and cortical bone structure.
- Reduced osteoclast-associated bone resorption.
Short summary: Romosozumab does not replace bone biology. It changes the instructions being received by the bone-remodelling system.
How the Wnt pathway enters the picture
The problem: osteoblasts need a clear growth signal
One of the most important signalling systems in bone is the Wnt pathway. Wnt proteins act like messages passed between cells. When canonical Wnt signalling is active, it can promote the development and function of osteoblasts.
A simplified version looks like this:
- Wnt binds to receptors on an osteoblast-lineage cell.
- The signal involves the co-receptors LRP5 and LRP6, meaning low-density lipoprotein receptor-related proteins 5 and 6.
- The intracellular messenger β-catenin becomes more stable.
- Gene activity changes in a way that supports osteoblast differentiation and bone formation.
Sclerostin interferes with this process by interacting with the LRP5/6 receptor system. In practical terms, it partially closes the communication channel between the Wnt message and the bone-forming cell.
The solution: restore the signal
Romosozumab neutralises sclerostin, allowing Wnt signalling to proceed more effectively. The analogy is a zipper:
- Wnt signalling helps close the zipper between the biological instruction and the osteoblast response.
- Sclerostin pulls the zipper open.
- Romosozumab blocks sclerostin, helping the zipper stay closed.
This pathway is one reason romosozumab has attracted interest in bone biology research. It demonstrates how a targeted antibody can influence a complex tissue-level process through a specific extracellular regulator.
